Urologix Inc ULGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.01
- Market Cap
- $2,181.77
- Volume/Avg
- 14,550 / 7,850
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 61
- Website
- http://www.urologix.com
Valuation
|
Metric
|
ULGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ULGX
|
|---|---|
Quick Ratio | 0.31 |
Current Ratio | 0.56 |
Interest Coverage | −5.12 |
Quick Ratio
ULGX
Profitability
|
Metric
|
ULGX
|
|---|---|
Return on Assets (Normalized) | −27.09% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ULGX
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Crkwyty | Jxtfvg | $185.4 Bil | |
SYK
| Stryker Corp | Qgrwggyynr | Fqpnb | $127.7 Bil | |
BSX
| Boston Scientific Corp | Zfkspqm | Hpxdxd | $107.6 Bil | |
MDT
| Medtronic PLC | Tcbqbfly | Rmhfp | $105.9 Bil | |
DXCM
| DexCom Inc | Bvzntnrp | Ghbg | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Kjntrfhtrr | Dknsyx | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Xwqmjpqtf | Xdtgt | $24.6 Bil | |
ALGN
| Align Technology Inc | Mrwfgbjk | Tdszf | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Fqsbglvn | Sqfbhs | $18.7 Bil | |
PODD
| Insulet Corp | Vwtkxkkkhf | Dhkjjx | $11.6 Bil |